Close

Alnylam Pharma (ALNY) Reports Positive 18-Month Results from HELIOS-A Phase 3 Study

Go back to Alnylam Pharma (ALNY) Reports Positive 18-Month Results from HELIOS-A Phase 3 Study

Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

January 21, 2022 7:30 AM EST

Vutrisiran Met All 18 Month Secondary Endpoints, Including Statistically Significant Improvements in Neuropathy Impairment, Quality of Life (QoL), Gait Speed, Nutritional Status and Overall Disability, Relative to External Placebo

Vutrisiran Continued to Demonstrate Halting or Reversal of Polyneuropathy, with Improvements in Neuropathy Impairment and QoL Relative to Baseline

Exploratory Cardiac Data, Including Reduced Technetium Uptake Relative to Baseline in Majority of Assessable Patients, Continue to Support Potential for Vutrisiran to Reduce Cardiac Amyloid Burden and Improve Cardiac Manifestations of Disease

In Addition, Vutrisiran Continued to Demonstrate Encouraging Safety and... More